Common painkiller could boost immunotherapy in lung cancer

NCT ID NCT06731270

First seen Feb 17, 2026 · Last updated Apr 29, 2026 · Updated 11 times

Summary

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen while on immunotherapy alone. About 20 adults with stage III or IV lung cancer who have been on a single immunotherapy drug for at least 12 weeks will receive diclofenac alongside their current treatment. The goal is to see if this combination can stabilize the cancer or shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.